PARTNERING FOR GLOBAL HEALTH

Transcription

1 PARTNERING FOR GLOBAL HEALTH

2 CONTENTS SaNOfi WE are WhErE you are a NEW partnership paradigm acquisitions and OuT-LiCENSiNg SaNOfi at a glance CONTaCT us Cover: Structure of Infectious Bursal Disease Virus (IBDV)

3 Partnership is at the core of what we do. It is how we foster increased innovation internally. It is how we assist our partners to go beyond their goals. And most importantly, it is the way we ensure we are delivering the best, the most innovative and the most awaited for solutions that patients are hoping for. New scientific discoveries are happening every day, but there is a significant challenge in translating these breakthroughs in the laboratory to treatments for patients. We realized that while we have some great expertise and science inside our own walls, it is through forming effective external partnerships that we could truly deliver on our commitment to patients. But it is not enough to simply sign a deal. We have become recognized as a great partner and the key to our success is based on a number of elements. First, we are looking to create deep, long-lasting partnerships, not just to solely finance projects. We also want to create a scientific community amongst our partners, creating a network of the best scientists around the world, internally and externally. We also understand that the management of partnerships, ensuring the right balance between our company and our partners, is as important as the project itself. We put a lot of focus on the development of each individual partnership: building a collaborative team, setting clear milestones and expectations together at the outset, and ensuring transparency between internal and external team members. Christopher A. Viehbacher Chief Executive Officer Sanofi 3 And, at the core of it all, the one element that is the real key to success the trust we strive for within the partnerships.

4 SaNOfi The value Sanofi has always placed on partnership is one of the reasons we are the global healthcare leader we are today. Some of our most well-known therapies, Plavix, Ambien, Taxotere and Eloxatin, are the result of partnerships, as is more than half of our current development portfolio. This heritage sustains our commitment to bring partnership into every sector of our business, a commitment that has resulted in collaborations with some of the world s foremost scientific organizations. Partnership is in our DNA. We are a diversified global healthcare leader, focused on the growing needs of patients, regulators and payers to improve healthcare outcomes innovatively and cost effectively. Like you, we are driven by our passion to transform scientific innovation into hope and solutions. Sanofi has core strengths in the field of healthcare with seven growth platforms: Emerging Markets, Human Vaccines, Consumer Healthcare, Diabetes, Innovative Products, Animal Health and the new Genzyme, which focuses on rare diseases and multiple sclerosis. HUMAN VACCINES DIABETES INNOVATIVE PRODUCTS ANIMAL HEALTH CONSUMER HEALTHCARE EMERGING MARKETS NEW GENZYME Our international presence and broad range of scientific expertise are world class. Even so, we are aware that no company has a monopoly on innovation and that there is no single way to advance a new idea. 4 Because any one target or pathway may impact multiple disease states, Sanofi welcomes innovative partnerships for all types of therapies in all therapeutic areas. We are committed to creating an open and creative partnership model. If you are working on something new with potential value for patients, we encourage you to contact us.

5 5

6 6

7 WE are WhErE you are Many entrepreneurs one enterprise Our partners find that whatever their stage and structure, geographic location, market reach or therapeutic area, we are there. We are there because Sanofi is a network of small and large operating units, global and regional groups, and integrated and independent businesses. This flexibility in structure is deliberate. It enhances our ability to anticipate and meet patients needs from overthe-counter medicines to prescription treatments and preventive therapies. It gives us the capacity to choose among technologies to produce the best outcomes, ranging from biologics to vaccines and nano-technologies or small molecules. Where our partners are concerned, it makes Sanofi more easily accessible and personal. If your organization is global or regional, we are there. Sanofi is international, but like our partners and the patients we serve, we live locally throughout the world. Unique in the industry, our employees are based almost equally across Europe and Japan, North America, and the world s emerging countries. Our strategies, structures and offerings are networked globally and tailored to each region s distinct needs. This connectivity has helped make Sanofi an industry leader in the study and application of real world needs and outcomes to guide the development of new healthcare solutions. As a result, our partners benefit from Sanofi s relationships with regulatory and marketing experts around the world and from our premier position in the world s fast-growing emerging markets. Our partners rely on us to show the way through each region s complex economic, cultural, healthcare and research environments so that we can create value together. 7

8 Whatever your therapeutic area, we are there. Sanofi has an open approach to all biological and pharmaceutical opportunities. In 2011, Sanofi acquired Genzyme, a company that has pioneered the development and delivery of transformative therapies for patients affected by rare diseases. In the same year, Merial was completely integrated into Sanofi, with a focus on developing, producing and marketing innovative medicines and vaccines for livestock and pets. We continue to look for additional external opportunities to contribute to our sustainable growth. The diversity of our business is reflected in our interest in a wide array of therapeutic areas, including but not limited to: Oncology Cardiovascular Vaccines Diabetes Ophthalmology Multiple Sclerosis Sanofi-Genzyme Research Center Immune-mediated diseases Infectious diseases Rare diseases Degenerative diseases of the elderly Animal health Through the formation of the Sanofi-Genzyme Research Center, researchers have access to the resources and capabilities of the broader Sanofi research organization and our network of universities, research institutions, government organizations and other partners. While continuing to build on Genzyme s legacy of expertise in rare diseases such as lysosomal storage disorders, the Center has robust research efforts in the area of immunologic and neurologic diseases, including multiple sclerosis, and one of the industry s longest standing research programs in the field of gene therapy. From the beginning, partnering has been central to the culture of Genzyme. Beyond our own labs, we collaborate with patient organizations, universities, research institutions, private companies, and government organizations to discover and develop treatments addressing significant unmet needs for patients around the world. This comprehensive approach to partnering has given us the ability to change the lives of thousands of patients and their families and create hope where there was none before. David Meeker, MD President and CEO, Genzyme Sanofi values innovative partnerships In all types of therapies and in all therapeutic areas Sanofi s focus on patients has driven our historical and ongoing strategy to create long-term value by researching and delivering the best treatments whatever their type. This strategy has made Sanofi a world leader in vaccines, biologicals and in small molecules. This is why, in addition to our primary areas of interest, Sanofi welcomes innovative partnerships for all types of therapies in all therapeutic areas. 8

9 Groundbreaking collaborations with like-minded partners such as Sanofi are a hallmark of the Fox Foundation s approach and help us speed scientific advances with potential to improve the treatment of Parkinson s for patients today and in the future. Todd Sherer Chief Executive Officer, Michael J. Fox Foundation 9

10 A NEW PARTNERSHIP PARADIGM Sanofi is growing internally, as well as through partnerships and selective acquisitions, to meet the evolving healthcare needs of today s and tomorrow s world. We understand that partnerships, like ideas, do not flourish on assembly lines. Sanofi s partners are not obliged to fit into rigid or inappropriate structures. Instead, we personalize each partnership to meet the unique needs of each project and team. Attracting the Best From Early Discovery through Late-Stage Development This open, strategic approach to partnership has attracted some of the best innovators in the world to Sanofi. Many are renowned organizations. Others are not as well known, but are as extraordinary in their pioneering approach to a new science or technology. Sanofi s partnerships range from early discovery through late-stage development. Emerging Science Sanofi is very interested in partnerships to advance emerging science. We are convinced that potentially disruptive innovation can gain wider acceptance, more quickly, through collaborations. Our interests are wide ranging, including gene therapy, nano- and micro-technologies, complex materials, converging technologies, new technologies for personalized medicine, new classes of drugs and new approaches to improve drugability. For Shanghai Institutes for Biological Sciences (SIBS), doing basic research is our strength, but how to translate that research into clinical application is a challenge. Partnering with a company like Sanofi is a natural choice for us. The successful conversion of a SIBS invention into a drug candidate for cancer treatment with Sanofi in less than two years demonstrates the power of such partnerships. Dr. Jiarui Wu Vice President of Shanghai Institute of Biological Sciences 10 Our collaboration is a true partnership between scientists with very different strengths. The University of California, San Francisco (UCSF) is known for its deep understanding of the underlying biology of diabetes, while Sanofi has great expertise in screening compounds, identifying which molecules have potential, and moving them along to develop a new drug. Such an endeavor is almost impossible to accomplish in a single academic laboratory. Thus, both partners profit from the expertise of the other group. Matthias Hebrok, PhD Director of the University of California, San Francisco (UCSF) Diabetes Center

11 EUROPE ~ 56,400 employees NORTH AMERICA ~ 18,900 employees JAPAN ~ 3,200 employees AFRICA/MIDDLE EAST ~ 4,700 employees LATIN AMERICA ~ 9,700 employees ASIA PACIFIC ~ 19,000 employees Partnership Network Sanofi s partners enjoy the benefits of our global partnership network and the opportunity to connect with world-renowned experts in their field. Our partners gain immediate access to the mature markets of Europe, Japan and North America, as well as to the fast-growing emerging economies of Asia Pacific, Latin America, Africa and the Middle East where Sanofi holds the premier position in the industry. When we were looking for new partners, one thing that set Sanofi apart was a sense of urgency, which is aligned with what is driving Oxford Biotherapeutics. To be successful, we have to bring a product to market, but I think there s a shared passion to address the significant unmet medical need of cancer patients. We re very pleased that Sanofi continues to drive the product forward, which I think will ultimately benefit patients as well as our company. Christoph Rohlff CEO, Oxford Biotherapeutics 11

12 Chemical library, Toulouse, France Access to the Sanofi Compound Collection Find the right compounds for your targets By making our high-quality compound collection available for external screening, Sanofi is offering an unprecedented new type of partnership. Partners exposure to our compound collection will enhance the value of their target portfolios. Most importantly, we believe that exposing more compounds to more targets will lead to more therapeutic solutions more quickly, benefiting patients. 12 Sanofi owns a world-class compound collection proven to generate high-quality starting points to research programs. By giving other organizations access to a proprietary, drug-like screening set, we offer a powerful opportunity to create value by exposing our compounds to original targets and models, with the potential for collaboration and co-development of novel therapies. Hubert Haag Sourcing & External Business, Lead Identification Technologies, Sanofi

13 Japan Kawagoe Site, Sterile production unit Launch of Warp Drive Bio Exploring natural products to uncover new therapies In January 2012, Sanofi co-invested with two venture capital funds in Warp Drive Bio, an innovative start-up biotechnology company. Warp Drive Bio is an innovative biotechnology company, focusing on proprietary genomic technology to discover drugs of natural origin. Through the agreement, Warp Drive Bio gains access to Sanofi s strains library and natural product expertise and Sanofi will be granted certain access rights to Warp Drive Bio s technology and products, on a worldwide basis. This agreement enables Warp Drive Bio to advance its core research and development plan to proof of concept, while also maintaining the ability to secure additional partnerships. The innovative collaboration between Sanofi and Third Rock Ventures provides the opportunity to build significant value and the potential for venture capital levels of return. Importantly, it also enables us to advance and accelerate the development of our proprietary genomics platform, unlock nature s drugs and, ultimately, create breakthrough therapies for patients. Alexis Borisy Partner at Third Rock Ventures and interim Chief Executive Officer of Warp Drive Bio 13

14 acquisitions and OuT-LiCENSiNg Acquisitions Since January 2009, Sanofi has invested a total of approximately 24 billion in external growth. During 2012, Sanofi announced 26 new transactions, including 8 acquisitions and 18 major R&D alliances. We strengthened our Emerging Markets growth platform with the agreement to acquire Genfar S.A., a leading pharmaceuticals manufacturer headquartered in Bogota, Colombia and a major player in Colombia and the other countries in Latin America. Also, we acquired the rights to lines of generic products for Sub Saharan Africa and for Vietnam. With these acquisitions, Sanofi intends to become a market leader in both Colombia and Nigeria, and has expanded its portfolio of affordable pharmaceuticals in Latin America, Africa and Southeast Asia. Sanofi also strengthened its presence in biosurgery by acquiring a 100% equity interest in Pluromed, Inc., an American medical devices company. Pluromed has developed a proprietary polymer technology Rapid Transition Polymers pioneering the use of plugs that can be injected into blood vessels to improve the safety, efficacy and economics of medical interventions. Our animal health business was also reinforced in 2012 by the acquisition of Newport Laboratories, a privately held company based in Worthington, Minnesota, a leader in autogenous vaccines with a focus on swine and bovine production markets, and with the agreement to acquire the Animal Health Division of Dosch 22 Pharmaceuticals in India. When completed, this last acquisition will create a market entry for Merial in that country s strategically important and growing Indian animal health sector. Joining forces with Merial allows us to expand our expertise in the market and enhance the profitability of our customers through solution-based animal healthcare offerings. We will also be able to reach untapped markets in the U.S., and eventually, even bring our expertise to the rest of the world. Dr. Randy Simonson Chief Operating Officer, Newport Laboratories Out - Licensing Sanofi has begun a comprehensive review of compounds, leads, patents and technologies in our pipeline. Our objective is to identify those with potential for out-licensing or other appropriate forms of partnering. This is a new initiative to create long-term value. We are flexible, and as we progress in our review, we will be open to exchanging ideas towards establishing creative partnerships. 14

15 Sanofi Pasteur, Lyon, France Topaz Pharmaceuticals did not have a sales force to launch Sklice Lotion, a unique, single-treatment option that resolves most head lice infestations in one well-tolerated application. They sought a partnership with an organization that had expertise with pediatricians and launching products, so this is really a synergistic relationship for them and us. Joe Collins Sr. Director, Marketing, Sanofi Pasteur 15

16 SaNOfi at a glance A F F I L I A T E S 16 Sanofi is listed in Euronext and NYSE

17 A global healthcare leader A DIvERSIFIED OFFERING of medicines, consumer healthcare products, generics and animal health AN ADvOCATE FOR INNOvATION In emerging science and cutting-edge partnerships A WORLD LEADER IN HumAN vaccines A BROAD AND BALANCED PRESENCE in both traditional and emerging markets more than 110,000 EmPLOyEES IN 100 countries 2012 NET SALES: 34.9 billion GROWTH OF 4.7%(1) On a reported basis (1) 17

18 CONTaCT us We invite you to contact Sanofi to inquire about partnership opportunities. Our contacts are in the attached insert, listed by region. your regional contact, who will query you on your project and connect you with the Sanofi specialists dedicated to your area of interest. Thank you for your interest in Sanofi. We look forward to hearing from you. 18

19 CREDITS 2013 SANOFI Photos: Sanofi/The Science Picture Company (cover), Marthe Lemelle (p3), A. Wiseman / CAPA Pictures (p5), Denis Félix / Interlinks Image (p6), Getty Image/LWA/Dann Tardif (p9), Objectif News/Rémi Benoit (p12), Rapho/ Gérard Uféras (p13), Guillaume Ramon / Capa Pictures (p15, p18), Interlinks Image/Eric Larrayadieu (p17) FORWARD LOOKING STATEMENTS This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions. Although Sanofi s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Sanofi s annual report on Form 20-F for the year ended December 31, Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. 19

20 For more information about Sanofi, please visit our website ( Sanofi - 54 Rue la Boetie Paris cedex 08 - France